The use of combined oral contraceptives in patients with endometriosis
https://doi.org/10.33667/2078-5631-2023-3-14-20
Abstract
Endometriosis is a benign inflammatory hormone-dependent disease characterized by pain and infertility. It seriously affect women’s health., endometriosis is a chronic disease it requires long-term treatment. Currently, hormonal drugs are most widely used for the treatment of endometriosis, which is based on the endocrine mechanisms of its pathogenesis. Key points are estrogen dependence and progesterone resistance, which provide implantation of ectopic endometrial cells, reduce apoptosis and increase oxidative stress, inflammation and neuroangiogenesis. the pain and infertility is explained by hormonal and inflammatory changes, as well as the systemic diseases and psychiatric disorders often associated with endometriosis. Hormonal treatment of endometriosis is aimed at suppressing ovulation through inhibition of the hypothalamic-pituitary-ovarian axis, as well as directly on endometrioid implants. Gonadotropin-releasing hormone (GnRH) agonists and antagonists, progestins, combined oral contraceptives (COCs) are now offcially approved for use to relieve the symptoms of endometriosis. The review provides information on the current possibilities of hormonal therapy for endometriosis, based on an understanding of the pathogenesis of the disease.
About the Author
I. V. Kuznetsova
Vitbiomed+ Co.
Russian Federation
Russian Federation
Kuznetsova Irina V., DM Sci (habil.), prof., deputy General Director for Research
Moscow
References
1. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat. Rev. Endocrinol. 2019;15(11):666–682. DOI: 10.1038/s41574–019–0245-z
2. Kavoussi SK, Lim CS, Skinner BD, Lebovic DI, As-Sanie S. New paradigms in the diagnosis and management of endometriosis. Curr. Opin. Obstet. Gynecol. 2016;28(4):267–276. DOI: 10.1097/GCO.0000000000000288.
3. Vannuccini S, Clemenza S, Rossi M, Petraglia F. Hormonal treatments for endometriosis: The endocrine background. Rev. Endocr. Metab. Disord. 2022;23(3):333–355. DOI: 10.1007/s11154–021–09666-w
4. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nat. Rev. Dis Primers. 2018;4(1):9. DOI: 10.1038/s41572–018–0008–5
5. Shafrir AL, Farland LV, Shah DK, Harris HR, Kvaskoff M, Zondervan K, Missmer SA. Risk for and consequences of endometriosis: A critical epidemiologic review. Best. Pract. Res. Clin. Obstet. Gynaecol. 2018;51:1–15. DOI: 10.1016/j.bpobgyn.2018.06.001
6. Kobayashi H, Imanaka S, Nakamura H, Tsuji A. Understanding the role of epigenomic, genomic and genetic alterations in the development of endometriosis (review). Mol. Med. Rep. 2014 May;9(5):1483–505. DOI: 10.3892/mmr.2014.2057
7. Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum. Reprod. Update. 2013;19(4):406–418. DOI: 10.1093/humupd/dmt010
8. Reis FM, Coutinho LM, Vannuccini S, Batteux F, Chapron C, Petraglia F. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum. Reprod. Update. 2020;26(4):565–585. DOI: 10.1093/humupd/dmaa009
9. Patel BG, Lenk EE, Lebovic DI, Shu Y, Yu J, Taylor RN. Pathogenesis of endometriosis: Interaction between Endocrine and inflammatory pathways. Best Pract. Res Clin. Obstet. Gynaecol. 2018;50:50–60. DOI: 10.1016/j.bpobgyn.2018.01.006
10. Filippi I, Carrarelli P, Luisi S, Batteux F, Chapron C, Naldini A, Petraglia F. Different Expression of Hypoxic and Angiogenic Factors in Human Endometriotic Lesions. Reprod. Sci. 2016;23(4):492–497. DOI: 10.1177/1933719115607978
11. Barbe AM, Berbets AM, Davydenko IS, Koval HD, Yuzko VO, Yuzko OM. Expression and Signifcance of Matrix Metalloproteinase-2 and Matrix Metalloproteinas-9 in Endometriosis. J. Med. Life. 2020;13(3):314–320. DOI: 10.25122/jml-2020–0117
12. Han SJ, O’Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum. Reprod. Update. 2014;20(4):467–484. DOI: 10.1093/humupd/dmu002
13. Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endomyometrium in endometriosis and adenomyosis. Hum. Reprod. Update. 2014;20(3):386–402. DOI: 10.1093/humupd/dmt052
14. Leyendecker G, Bilgicyildirim A, Inacker M, Stalf T, Huppert P, Mall G. et al. Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study. Arch Gynecol. Obstet. 2015;291(4):917–932. DOI: 10.1007/s00404–014–3437–8
15. Gori M, Luddi A, Belmonte G, Piomboni P, Tosti C, Funghi L. et al. Expression of microtubule associated protein 2 and synaptophysin in endometrium: high levels in deep infltrating endometriosis lesions. Fertil Steril. 2016;105(2):435–443. DOI: 10.1016/j.fertnstert.2015.10.024
16. Guo SW. Fibrogenesis resulting from cyclic bleeding: the Holy Grail of the natural history of ectopic endometrium. Hum Reprod. 2018;33(3):353–356. DOI: 10.1093/humrep/dey015
17. Chamié LP, Ribeiro DMFR, Tiferes DA, Macedo Neto AC, Serafni PC. Atypical Sites of Deeply Infltrative Endometriosis: Clinical Characteristics and Imaging Findings. Radiographics. 2018;38(1):309–328. DOI: 10.1148/rg.2018170093
18. Vannuccini S, Tosti C, Carmona F, Huang SJ, Chapron C, Guo SW, Petraglia F. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed Online. 2017;35(5):592–601. DOI: 10.1016/j.rbmo.2017.06.016
19. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019; 8: F1000 Faculty Rev-283. DOI: 10.12688/f1000research.17242.1
20. Nirgianakis K, Ma L, McKinnon B, Mueller MD. Recurrence Patterns after Surgery in Patients with Different Endometriosis Subtypes: A Long-Term Hospital-Based Cohort Study. J. Clin. Med. 2020;9(2):496. DOI: 10.3390/jcm9020496
21. Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA. et al. Clinical diagnosis of endometriosis: a call to action. Am. J. Obstet. Gynecol. 2019;220(4):354.e1–354.e12. DOI: 10.1016/j.ajog.2018.12.039
22. De Graaff AA, D’Hooghe TM, Dunselman GA, Dirksen CD, Hummelshoj L; WERF EndoCost Consortium; Simoens S. The signifcant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. Hum. Reprod. 2013;28(10):2677–2685. DOI: 10.1093/humrep/det284
23. Brandes I, Kleine-Budde K, Heinze N, Binder S, Klug C, Schippert C. et al. Cross-sectional study for derivation of a cut-off value for identifcation of an early versus delayed diagnosis of endometriosis based on analytical and descriptive research methods. BMC Womens Health. 2022;22(1):521. DOI: 10.1186/s12905–022–02044-x
24. Tanbo T, Fedorcsak P. Endometriosis-associated infertility: aspects of pathophysiological mechanisms and treatment options. Acta. Obstet. Gynecol. Scand. 2017 96(6):659–667. DOI: 10.1111/aogs.13082
25. Fuldeore MJ, Soliman AM. Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. Gynecol. Obstet. Invest. 2017;82(5):453–461. DOI: 10.1159/000452660
26. Peterson CM, Johnstone EB, Hammoud AO, Stanford JB, Varner MW, Kennedy A, et al; ENDO Study Working Group. Risk factors associated with endometriosis: importance of study population for characterizing disease in the ENDO Study. Am. J. Obstet. Gynecol. 2013;208(6):451.e1–11. DOI: 10.1016/j. ajog.2013.02.040
27. Perelló M, Martínez-Zamora MA, Torres X, Munrós J, Llecha S, De Lazzari E, et al. Markers of deep infltrating endometriosis in patients with ovarian endometrioma: a predictive model. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017;209:55–60. DOI: 10.1016/j.ejogrb.2015.11.024
28. Saha R, Marions L, Tornvall P. Validity of self-reported endometriosis and endometriosis-related questions in a Swedish female twin cohort. Fertil. Steril. 2017;107(1):174–178.e2. DOI: 10.1016/j.fertnstert.2016.09.038
29. Ashraf M, Sadatmahalleh SJ, Akhoond MR, Talebi M. Evaluation of Risk Factors Associated with Endometriosis in Infertile Women. Int. J. Fertil. Steril. 2016;10(1):11–21. DOI: 10.22074/ijfs.2016.4763
30. Marinho MCP, Magalhaes TF, Fernandes LFC, Augusto KL, Brilhante AVM, Bezerra LRPS. Quality of Life in Women with Endometriosis: An Integrative Review. J. Womens Health (Larchmt). 2018;27(3):399–408. DOI: 10.1089/jwh.2017.6397
31. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil. Steril. 2014;101(4):927–935. DOI: 10.1016/j.fertnstert.2014.02.012
32. Clemenza S, Sorbi F, Noci I, Capezzuoli T, Turrini I, Carriero C, et al. From pathogenesis to clinical practice: Emerging medical treatments for endometriosis. Best Pract.Res Clin. Obstet. Gynaecol. 2018;51:92–101. DOI: 10.1016/j.bpobgyn.2018.01.021
33. Ceccaroni M, Bounous VE, Clarizia R, Mautone D, Mabrouk M. Recurrent endometriosis: a battle against an unknown enemy. Eur. J. Contracept. Reprod. Health Care. 2019;24(6):464–474. DOI: 10.1080/13625187.2019.1662391
34. Ianieri MM, Mautone D, Ceccaroni M. Recurrence in Deep Infltrating Endometriosis: A Systematic Review of the Literature. J. Minim Invasive Gynecol. 2018;25(5):786–793. DOI: 10.1016/j.jmig.2017.12.025
35. Ferrero S, Barra F, Leone Roberti Maggiore U. Current and Emerging Therapeutics for the Management of Endometriosis. Drugs. 2018;78(10):995–1012. DOI: 10.1007/s40265–018–0928–0
36. Федеральные клинические рекомендации «Эндометриоз». 2020 г. Federal clinical guidelines «Endometriosis». 2020
37. Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L. et al. ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum Reprod. Open. 2022;2022(2): hoac009. DOI: 10.1093/hropen/hoac009
38. Capezzuoli T, Vannuccini S, Mautone D, Sorbi F, Chen H, Reis FM. et al. Long-term hormonal treatment reduces repetitive surgery for endometriosis recurrence. Reprod. Biomed Online. 2021;42(2):451–456. DOI: 10.1016/j.rbmo.2020.09.018
39. Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical effcacy and safety of progestins for treating pain associated to endometriosis. Expert Opin. Drug Metab. Toxicol. 2018;14(4):399–415. DOI:10.1080/17425255.2018.1461840
40. Orazov M. R., Orekhov R. E. Personifcation of therapy for patients suffering from superfcial and deep infltrative endometriosis. Women's Clinic. 2022;1:37–47.
41. Orazov M.R. «Lifebuoy» for patients suffering from pelvic pain due to endometriosis. Women’s clinic. 2021;2:6–12.
42. Murji A, Biberoğlu K, Leng J, Mueller MD, Römer T, Vignali M, Yarmolinskaya M. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr. Med. Res Opin. 2020;36(5):895–907. DOI: 10.1080/03007995.2020.1744120
43. Chantalat E, Valera MC, Vaysse C, Noirrit E, Rusidze M, Weyl A. et al. Estrogen Receptors and Endometriosis. Int. J. Mol. Sci. 2020;21(8):2815. DOI: 10.3390/ijms21082815
44. Dyson MT, Roqueiro D, Monsivais D, Ercan CM, Pavone ME, Brooks DC. et al. Genome-wide DNA methylation analysis predicts an epigenetic switch for GATA factor expression in endometriosis. PLoS Genet. 2014;10(3): e1004158. DOI: 10.1371/journal.pgen.1004158
45. Sophonsritsuk A, Tantanavipas S, Tingthanatikul Y, Lertvikool S, Dittharot K, Waiyaput W. Effects of Ethinyl Estradiol in Combined Oral Contraceptives on Cell Proliferation and Apoptosis in Ectopic Endometrial Tissue: A Randomized Controlled Study. J. Family. Reprod. Health. 2021;15(1):45–52.
46. Bedaiwy M, Allaire C, Yong P. et al. Medical Management of Endometriosis in Patients with Chronic Pelvic Pain. Semin. Reprod. Med. 2017;35(1):38–53.
47. Koga K, Takamura M, Fujii T, Osuga Y. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil. Steril. 2015;104(4):793–801. DOI: 10.1016/j.fertnstert.2015.08.026
48. Dunselman GAJ, Vermeulen N, Becker C. et al. ESHRE guideline: management of women with endometriosis. Hum. Reprod. 2014;29(3):400–412.
49. Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst. Rev. 2018;5(5): CD 001019. DOI: 10.1002/14651858.CD001019.pub3
50. Ulrich U, Buchweitz O, Greb R. et al. For the German and Austrian Societies for Obstetrics and Gynecology. National German Guideline (S 2k): Guideline for the Diagnosis and Treatment of Endometriosis: Long Version – AWMF Registry No. 015–045. Geburtshilfe Frauenheilkd 2014;74(12):1104–1118.
51. Caruso S, Iraci M, Cianci S, Fava V, Casella E, Cianci A. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J. Endocrinol Invest. 2016;39(8):923–931.
52. Zakhari A, Delpero E, McKeown S, Tomlinson G, Bougie O, Murji A. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum. Reprod. Update. 2021;27(1):96–107. DOI: 10.1093/humupd/dmaa033
53. Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil. Steril. 2017;108(1):125–136. DOI: 10.1016/j.fertnstert.2017.05.004
54. Caruso S, Iraci M, Cianci S, Vitale SG, Fava V, Cianci A. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. J. Pain. Res. 2019;12:2371–2378. DOI: 10.2147/JPR.S207599
55. Leone Roberti Maggiore U, Remorgida V, Scala C, Taf E, Venturini PL, Ferrero S. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infltrating the rectum: a prospective open-label comparative study. Acta. Obstet. Gynecol. Scand. 2014;93(3):239–247. DOI: 10.1111/aogs.12326
56. Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur. J. Obstet. Gyneco.l Reprod. Biol. 2014;179:63–68. DOI: 10.1016/j.ejogrb.2014.05.016
57. Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, Somigliana E. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril. 2016;105(3):734–743.e3. DOI: 10.1016/j.fertnstert.2015.11.016
58. Carr B, Dmowski WP, O’Brien C, Jiang P, Burke J, Jimenez R. et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod. Sci. 2014;21(11):1341–1351. DOI: 10.1177/1933719114549848
59. Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N. Engl.J. Med. 2017;377(1):28–40. DOI: 10.1056/NEJMoa1700089
60. Tsai HW, Wang PH, Huang BS, Twu NF, Yen MS, Chen YJ. Low-dose add-back therapy during postoperative GnRH agonist treatment. Taiwan J Obstet Gynecol. 2016;55(1):55–59. DOI: 10.1016/j.tjog.2015.04.004
61. Priya K, Rajaram S, Goel N. Comparison of combined hormonal vaginal ring and low dose combined oral hormonal pill for the treatment of idiopathic chronic pelvic pain: a randomised trial. Eur J Obstet Gynecol Reprod Biol. 2016;207:141–146. DOI: 10.1016/j.ejogrb.2016.10.026
62. Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A, Facchinetti F. Hormonal contraception in women with endometriosis: a systematic review. Eur. J. Contracept. Reprod. Health Care. 2019;24(1):61–70. DOI:10.1080/13625187.2018.1550576
63. Muzii L, Di Tucci C, Achilli C, Di Donato V, Musella A, Palaia I, Panici PB. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016;214(2):203–211. DOI: 10.1016/j.ajog.2015.08.074
Review
For citations:
Kuznetsova I.V. The use of combined oral contraceptives in patients with endometriosis. Medical alphabet. 2023;(3):14-20. (In Russ.) https://doi.org/10.33667/2078-5631-2023-3-14-20
Views:
318
Email this article 